Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Bausch & Lomb Inc. (BOL)
Financials 
Technical Analysis 0
BUY
HOLD
Had a misstep on a contact lens solution and the stock dropped to the mid-$40's. He bought at that level, because even if all of their contact lens solution went to zero, they still had other businesses. Recent rumours have driven the stock up to $60.
Pat NaccaratoOwned
biotechnologypharmaceutical
TOP PICK
Has gone through a transition. Was suffering a few years ago when it lost its momentum, R&D lagged. Can see some growth opportunity in their new lens. New president has shaken down the company, cut costs and re-invigorated their R&D. Has exceeded expectations for 13 quarters.
Ian AinsworthOwned
biotechnologypharmaceutical
Showing 1 to 5 of 5 entries
- «
- ‹
- 1
- ›
- »
Bausch & Lomb Inc. (BOL) Frequently Asked Questions
What is Bausch & Lomb Inc. stock symbol?
Bausch & Lomb Inc. is a OTC stock, trading under the symbol BOL (previously BOL-N on Stockchase) on the undefined (undefined). It is usually referred to as or BOL
Is Bausch & Lomb Inc. a buy or a sell?
In the last year, no analyst issued a Buy, Sell, or Hold rating on BOL (previously BOL-N on Stockchase) on Stockchase. Read the latest expert commentary for Bausch & Lomb Inc..
Is Bausch & Lomb Inc. a good investment or a top pick?
Bausch & Lomb Inc. was recommended as a Top Pick by Ian Ainsworth on 2005-05-27. Read the latest stock experts ratings for Bausch & Lomb Inc..
Why is Bausch & Lomb Inc. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Bausch & Lomb Inc..
Is Bausch & Lomb Inc. worth watching?
Bausch & Lomb Inc. is covered by Stockchase experts and is worth watching.
It just reported clean top and bottom line beats with good results across all three divisions. Management raised its full-year sales forecast.